A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Memorial Sloan Kettering Cancer Center
Verastem, Inc.
Aulos Bioscience, Inc.
AstraZeneca
Regeneron Pharmaceuticals
Novartis
M.D. Anderson Cancer Center
Frontier Medicines Corporation
PMV Pharmaceuticals, Inc
Mayo Clinic
M.D. Anderson Cancer Center
Avenzo Therapeutics, Inc.
Tasca Therapeutics
Essen Biotech
Essen Biotech
Revolution Medicines, Inc.
Incyte Corporation
DualityBio Inc.
Kidney Cancer Research Bureau
Second Life Therapeutics
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Pfizer
VM Oncology, LLC
Takeda
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
Transgene
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Hadassah Medical Organization
Centre Georges Francois Leclerc
GI Innovation, Inc.
Immuneering Corporation
Incyte Corporation
Sensei Biotherapeutics, Inc.
Incyte Corporation
Yuhan Corporation
NuCana plc
Medicenna Therapeutics, Inc.
Verastem, Inc.
Hutchmed
NextCure, Inc.
Kymab Limited
Phanes Therapeutics
Immunophotonics, Inc.
OncoResponse, Inc.
Deciphera Pharmaceuticals, LLC
NextCure, Inc.
Mundipharma Research Limited